Cost-effectiveness analysis comparing ceftazidime/avibactam (CAZ-AVI) as empirical treatment comparing to ceftolozane/tazobactam and to meropenem for complicated intra-abdominal infection (cIAI) | Antimicrobial Resistance & Infection Control | Full Text

Cost-effectiveness analysis comparing ceftazidime/avibactam (CAZ-AVI) as empirical treatment comparing to ceftolozane/tazobactam and to meropenem for complicated intra-abdominal infection (cIAI) | Antimicrobial Resistance & Infection Control | Full Text

Cost-effectiveness analysis comparing ceftazidime/avibactam (CAZ-AVI) as empirical treatment comparing to ceftolozane/tazobactam and to meropenem for complicated intra-abdominal infection (cIAI)

The rising incidence of resistance to currently available antibiotics among pathogens, particularly Gram-negative pathogens, in complicated intra-abdominal infections (cIAIs) has become a challenge for clinici...

Authors:Thitima Kongnakorn, Christian Eckmann, Matteo Bassetti, Eszter Tichy, Roberto Di Virgilio, Nathalie Baillon-Plot and Claudie Charbonneau

Citation:Antimicrobial Resistance & Infection Control 2019 8:204

Content type:Research

Published on: 21 December 2019

• ViewFull Text
 
• ViewPDF